Vivos Therapeutics Inc.
VVOS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for VVOS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · VVOS
Vivos Therapeutics Inc. (VVOS) is a medical technology company focused on developing and commercializing treatments for sleep-related breathing disorders, including its proprietary DNA oral appliance therapy, while facing significant financial and operational challenges.
Key risk: Going concern risk
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Vivos Therapeutics Inc. (VVOS) is a medical technology company focused on developing and commercializing treatments for sleep-related breathing disorders, including its proprietary DNA oral appliance therapy, while facing significant financial and operational challenges.
- Cash and equivalents of $1.8M as of 2026-06-30 [sec].
- Total revenue of $5.2M for the six months ended 2026-06-30 [sec].
- Net loss of $5.5M for the six months ended 2026-06-30 [sec].
- Shareholders' equity of -$1.5M as of 2026-06-30 [sec].
- Total debt of $8.4M as of 2026-06-30 [sec].
What works
- The company has a pipeline of potential acquisition and management opportunities with sleep centers, which it believes will be a key driver of future accretive growth [sec_mda · as of 2025-08-19].
- Revenue increased in the quarter ended September 30, 2025, following the first full quarter of SCN operations [sec_mda · as of 2025-11-19].
- The company has implemented cost savings measures that have reduced cash used in operations [sec_mda · as of 2026-05-20].
What to weigh
- The company has incurred losses since inception, with an accumulated deficit of approximately $113.1 million as of June 30, 2025 [sec_mda · as of 2025-08-19].
- Substantial doubt exists regarding the company's ability to continue as a going concern without additional financing [sec_mda · as of 2026-05-20].
- Sales did not grow in 2025 and for the three months ended March 31, 2026 as much as anticipated, and revenue from a key alliance with Rebis Health did not develop as expected [sec_mda · as of 2026-05-20].
- A clinical hold on a study for the DNA device may not be lifted in a timely manner, and the trial may not meet its designated endpoints, potentially delaying FDA clearances [sec_mda · as of 2026-08-14].
From the filings
Quoted directly from source documents.
Substantial doubt about going concern
“we have both near and long term cash requirements to operate our business, and without additional financing, these factors raise substantial doubt regarding our ability to continue as a going concern.”
SEC MD&A · May 20, 2026
Accumulated deficit
“resulting in an accumulated deficit of approximately $113.1 million as of June 30, 2025.”
SEC MD&A · August 19, 2025
Clinical hold risk
“there can be no assurance that the hold will be lifted in a timely manner, or at all. Any delay or failure to resolve the issues could impact the development timeline and future prospects for the study.”
SEC MD&A · August 14, 2026
Revenue growth from SCN operations
“This trend began to shift materially in the quarter ended September 30, 2025 as we experienced our first full quarter of SCN operations and resulting in increases in revenue.”
SEC MD&A · November 19, 2025
Risks & what to watch (4)›
Key risks
- Going concern risk — Substantial doubt about ability to continue as a going concern without additional financing [sec_mda · as of 2026-05-20].
- Clinical hold on DNA device — FDA clinical hold may not be lifted, delaying or preventing clearance for the DNA device [sec_mda · as of 2026-08-14].
- Revenue shortfall — Sales did not grow as anticipated in 2025 and early 2026, and a key alliance underperformed [sec_mda · as of 2026-05-20].
- High accumulated deficit — Accumulated deficit of approximately $113.1 million as of June 30, 2025 [sec_mda · as of 2025-08-19].
What to watch
- Ability to secure additional financing to address going concern and fund operations [sec_mda · as of 2026-05-20].
- Resolution of the FDA clinical hold on the DNA device study and any updates on trial endpoints [sec_mda · as of 2026-08-14].
- Revenue growth trajectory, particularly from SCN operations and distribution collaborations [sec_mda · as of 2025-11-19].
- Progress in sleep center acquisition pipeline and its impact on financial performance [sec_mda · as of 2025-08-19].
Sources: SEC filings · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Vivos Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Vivos Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
2.4 months
OCF -$3M · Net income -$5M
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
5 buys · 0 sells (180d)
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
21
Total value held
$2.0M
| Holder | Shares | Value |
|---|---|---|
| armistice capital, llc | 1,115,859 | $1.3M |
| vanguard capital management llc | 273,329 | $323K |
| geode capital management, llc | 95,543 | $113K |
| commonwealth equity services, llc | 42,500 | $50K |
| vanguard fiduciary trust co | 30,832 | $36K |
| blackrock, inc. | 27,817 | $33K |
| xtx topco ltd | 25,117 | $30K |
| state street corp | 24,922 | $29K |
| sequoia financial advisors, llc | 24,000 | $28K |
| acorn wealth advisors, llc | 14,776 | $17K |
Showing top 10 of 21 institutional holders of Vivos Therapeutics Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 13, 2026- % of float
- 6.6%
- Days to cover
- 1.9
- Shares short
- 716,108
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
VVOS short interestGovernance
Frequently asked questions
What is the AI investment thesis for Vivos Therapeutics Inc.?
Vivos Therapeutics Inc. (VVOS) is a medical technology company focused on developing and commercializing treatments for sleep-related breathing disorders, including its proprietary DNA oral appliance therapy, while facing significant financial and operational challenges.
Who is the CEO of Vivos Therapeutics Inc.?
Mr. R. Kirk Huntsman is the chief executive officer of Vivos Therapeutics Inc. (VVOS).
Where is Vivos Therapeutics Inc. headquartered?
Vivos Therapeutics Inc. (VVOS) is headquartered in Littleton, CO, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.